Логин: Пароль: ?
 
Продукты питания Ткань, одежда, обувь, постельное белье, текстиль Строительные материалы Бумага, пластик, промтовары Биотопливо Продукция для сельского хозяйства, зоотовары Косметика, средства гигиены Медицинские товары и препараты, лекарства Иное

 

Наши партнеры:

 

Новости/Аналитика

According to EUMCA Chair, increasing THC levels in products jeopardizes patient safety

06.07.2020

Since extracts are made by different manufacturers using different varieties of hemp plants, different extraction methods are used, as there is no clear concept of “hemp extract” or “cannabis extract” in the regulatory framework. Those. the same products made from the same hemp varieties, even using the same extraction methods, differ significantly. If government agencies care about patients, they should develop a regulatory framework that will oblige manufacturers of cannabinoid products to declare the following information about products on the market: variety used; exact contents of CBD, CBDA, THC, THCA, CBC, CBG; the exact content of at least the following terpenes is β-caryophyllene, caryophyllene oxide, alpha-humulene, myrcene, alpha-pinene, gamma-terpinene. 

For quite a long time, the issue of a rather active issue by our European colleagues about the need to increase the amount of tetrahydrocannabinol (THC) in hemp products to 0.3% was not addressed on the pages of the profile electronic publication of Ukrainian hemp breeders. Considering the fact that during lobbying for amendments to the current regulatory legal acts of our country, similar questions are raised about increasing the number of TGCs from the current value of 0.08 to 0.2% and the unconfirmed information is given as arguments about the appropriateness of using cannabis varieties with a high content of tetrahydrocannabinol for patients, we will offer for familiarization by our esteemed readers the position on this issue of the chairman of the European Medical Cannabis Association Trevor Jones. 

Professor Jones argues that increasing the amount of THC in the final product, which can be used as a therapeutic agent up to 0.3%, jeopardizes the safety of patients. In particular, during a meeting with media representatives, Mr. Jones said that “The current limit of 0.2% of the amount of THC has been set to reduce and prevent abuse of hemp extracts. Some European market experts argue that for safety reasons even lower tetrahydrocannabinol limits should be set for products that the customer has free access to. Raising the limit to 0.3% should be allowed only if there is evidence from clinical trials with a sufficient number of sources that use products with a clearly defined content that this higher limit is acceptable safe in populations of consumers of different ages. In addition, for example, German law regulating the attitude of state authorities to psychoactive substances clearly states that the lower limit of the amount of THC should be 0.2%, therefore, even if the relevant EU Directive is adopted, it will be contrary to the regulatory legal acts of a number of European states ".

According to Mr. Jones, another key problem is the fact that different hemp varieties with the same tetrahydrocannabinol and cannabidiol content have different effects on patients when extracts from leaves and inflorescences of plants used for medicinal purposes are used. Studies suggest that extracts of the same cannabinoid made using different technologies have completely different effects on the patient’s body. In particular, Mr. Jones claims that “Since extracts are made by different manufacturers using different varieties of hemp plants, different extraction methods are used, as there is no clear concept of“ hemp extract ”or“ cannabis extract ”in the regulatory framework . Those. the same products made from the same hemp varieties, even using the same extraction methods, differ significantly. If government agencies care about patients, they should develop a regulatory framework that will oblige manufacturers of cannabinoid products to declare the following information about products on the market: variety used; exact contents of CBD, CBDA, THC, THCA, CBC, CBG; the exact content of at least the following terpenes is β-caryophyllene, caryophyllene oxide, alpha-humulene, myrcene, alpha-pinene, gamma-terpinene. "

Commentary by the Ukrainian Technical Hemp Association

Professor Trevor Jones is Chairman of the European Medicinal Cannabis Association (EUMCA). An EU industry body advocating for a European science-based policy to improve patient access to high-quality hemp treatment.

The position of Mr. Jones at least speaks of the following points:

- once again, the correctness of careful attention to quality control issues of hemp products on the market by government agencies of the USA, Great Britain, and the EU, which provide for the launch of cannabinoid products on the market only after they can confirm their safety for the consumer, is confirmed. Including this is due to the fact that during the extraction process, hemp products manufacturers, in the pursuit of profit, make products that negatively affect the human body;

- given the unresolved issue of the content of therapeutic elements in the final product, manufacturers in North America, Europe, and especially China are guilty of using cannabinoids primarily as a marketing tool to attract customers to products that do not have therapeutic properties;

- making any changes to the current regulatory framework cannot be based on the lobbyism of any structures. The basis should be the relevant research carried out by scientific institutions that specialize in this kind of problems;

- therapeutic properties are possessed not only by cannabinoids, which Professor Jones speaks of, but also other elements of the plant, for example, terpenes. Given the number of elements that Mr. Jones believes should be indicated, the complex use of the therapeutic properties of hemp plants, that is, the use of the “ensemble effect” during treatment, is proposed;

- the absence of any regulatory framework in matters related to the regulation of the use of therapeutic properties of hemp in our country, as well as the inability to determine the therapeutic potential of cannabinoid products purchased by citizens of Ukraine via the Internet, implies a huge share of “garbage goods”, which are overwhelmingly imported Ukrainian market.

Обучение в рамках "Конопляного Университета"
15.09.2020

Объявления
Все объявления »
 
 

facebook

telegram

twitter